Maintenance. We are currently updating the site. Please check back shortly

Thomson Reuters Foundation

Inform - Connect - Empower

EXCLUSIVE-Canada to donate its own Ebola vaccine to WHO for use in Africa

Source: Reuters - Tue, 12 Aug 2014 23:30 GMT
Author: Reuters
hum-dis
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

(Updates with Canada donation)

By Rod Nickel

WINNIPEG, Manitoba, Aug 12 (Reuters) - Canada will donate a small quantity of an experimental Ebola vaccine developed in its government lab to the World Health Organization for use in Africa, the country's health minister said on Tuesday.

The decision to donate the vaccine came after the WHO said on Tuesday that it was ethical to offer untested drugs to people infected by the virus.

The Canadian government will donate between 800 to 1,000 doses of the vaccine, with the final number given dependent on how much Canada holds back for research and clinical trials. The government will also keep a small supply in case it is needed domestically.

Health Minister Rona Ambrose said she offered the vaccine to Dr. Margaret Chan, director general of the WHO.

The U.S. is also working on a vaccine and the WHO and governments involved were discussing possible use in Africa, Dr. Greg Taylor, deputy chief public health officer of the Public Health Agency of Canada told Reuters in an interview ahead of the Canadian announcement.

Canada only has about 1,500 animal doses of the vaccine, which it invented a few years ago, and would need four to six months to make a large quantity, he said. The government's vaccine is separate from the treatment being developed by Canada's Tekmira Pharmaceuticals Corp.

"We see this as a global resource, something we need to put on the global table to say ... how can we make best use of this asset? "We're looking to do that as fast as we can," Taylor said, speaking from Ottawa.

The Ebola outbreak is the world's largest and deadliest. So far, 1,013 people have died, the vast majority in Guinea, Liberia and Sierra Leone.

The Canadian vaccine, which the agency licensed for commercialization to U.S. firm BioProtection Systems, a unit of Newlink Genetics, has proven effective in animals but has never been tested in humans, Taylor said.

Last week, Iowa-based NewLink said that BioProtection had a contract with the U.S. Department of Defense for studies to bring the Canadian Ebola vaccine closer to human testing.

"We've been trying to figure out how we can make a contribution in the fight against this disease and get our vaccine into the clinic," Brian Wiley, NewLink vice-president of business development, told Reuters on Tuesday. "A large amount of work still needs to be done, but when there is a dire need the powers that be move at a quicker pace."

Canada's Taylor did not specify which of several U.S. vaccines in development he was referring to that may be used in Africa along with the Canadian vaccine.

Profectus BioSciences of Tarrytown, New York, has tested its Ebola vaccine in monkeys with good results, its chief science officer John Eldridge said on Tuesday.

Still, deciding whether to use an experimental drug on humans is "very difficult," Taylor said.

"You really don't know how safe it is, you don't know what the side effects are going to be. But in this extraordinary circumstance in Africa right now, we're trying to do everything we can to assist."

The first doses in Africa would likely be available to health care workers, Taylor said.

The Public Health Agency of Canada was also involved in the development of ZMapp, an experimental Ebola treatment licensed by U.S. firm Mapp Biopharmaceutical that has been used to treat two infected American aid workers. Liberia said on Tuesday it will get Mapp's drug to treat two doctors. (Additional reporting by Sharon Begley in New York; Editing by Amran Abocar, Bernard Orr)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
Most Popular
TOPICAL CONTENT
Topical content
LATEST SLIDESHOW

Latest slideshow

See allSee all
FEATURED JOBS
Featured jobs